Please Login to participate

Course HomeCourse Progress
  • Pre-Test
  • Download PDF of Slides
  • Access Webcast
  • Evaluation
  • Certificate

Incorporating Targeted Therapies into Care for Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia


John Allan, MD
Assistant Professor of Medicine
Weill Cornell Medicine
New York, New York

Othman Al-Sawaf, MD
University Hospital of Cologne
Cologne, Germany

Jennifer R. Brown, MD, PhD
Director, CLL Center & Institute Physician
Worthington and Margaret Collette
Professor of Medicine in the filed of Hematology/ Oncology
Dana-Farber Cancer Institute
Harvard Medical School

Jan Burger, MD, PhD
Professor, Department of Leukemia
Division of Cancer Medicine
MD Anderson Cancer Center

Asher Chanan-Khan, MD
Professor of Medicine
Mayo Clinic
Jacksonvilee, Florida

Alexey Danilov, MD
Professor, City of Hope
Comprehensive Cancer Center
La Canada, California

Richard R. Furman, MD
Morton Coleman, MD Distinguished Professor of Medicine
New York Presbyterian Hospital
Weill Cornell Medicine, New York

Michael Hallek, MD
Morton Coleman, MD Distinguished Professor of Medicine
New York Presbyterian Hospital
Weill Cornell Medicine, New York

Neil Kay, MD
Mayo Clinic
Rochester, Minnesota

Anthoby Mato, MD, MSCE
Associate Member, Director of the Chronic Lymphocytic Leukemia Program
Memorial Sloan Kettering Cancer Center
New York, New York

Javed Moslehi, MD
Associate Professor, Medicine
University of California, San Francisco
San Francisco, California


Provided by HMP Education, an HMP Global Company.

For questions regarding this educational activity, or to cancel your account, please call 609-371-1137 or email


This activity is designed for hematologists, hematologists/oncologists, PAs, NPs, nurses, and pharmacists who specialize in hematology, as well as other HCPs who care for patients with hematologic malignancies.


After participating in this activity, learners should be better able to:

  • Identify the relevant genetic mutations in CLL/SLL which may influence treatment outcomes

  • Evaluate safety and efficacy data of new and emerging targeted agents for CLL/SLL treatment

  • Explain the importance of cytogenetic analysis and minimal residual disease (MRD) monitoring CLL/SLL patient care


This on-demand webcast is available with synchronized slides and video/audio.

. To be eligible for credit, participants must complete the educational activity, complete the 5-question post-test with a minimum score of 70%, and complete the activity evaluation form. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.

Release Date: November 28, 2022 
Expiration Date: November 27, 2023
Estimated Time to Complete: 4.5 hour

There is no fee associated with this activity.


The activity is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. 


Joint Accreditation with commendation logoIn support of improving patient care, HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Note: This statement is not an indication of approved credits. Please see below for full accreditation details, including credit types and totals, for this activity.


HMP Education designates this internet enduring activity for a maximum of 4.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This internet enduring, knowledge-based activity (Universal Activity Number: UAN JA0006201-0000-22-199-H04-P) has been approved for a maximum of 4.5 contact hours (.5 CEUs).

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in the CPE Monitor system. Following ACPE Policy, HMP Education must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity. HMP Education is not able to report your claimed credit after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended.


This continuing nursing education internet enduring activity awards 4.5 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 4.5 contact hours. 


American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 CreditTM from organizations accredited by the ACCME.


AAPA logoHMP Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s)  for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 4.5 AAPA Category 1 credit(s). Approval is valid until November 28, 2023.] PAs should only claim credit commensurate with the extent of their participation.



The following Countries, Regions, and Accrediting Bodies accept, or have reciprocity or mutual recognition of credits with the AMA/ACCME. Please contact the accrediting body to find out more information on submitting or converting your credits.

  • Bavarian Chamber of Physicians (Germany)
  • Bulgarian Union of Scientific Medical Societies (Bulgaria)
  • Canadian Medical Association (Canada)
  • Canadian Nurses Association (Canada)
  • EBAC® (European Board for Accreditation of Continuing Education for Health Professionals)
  • Federation of Royal Colleges of Physicians (UK)
  • French National Medical Council (France)
  • Italian Federation of Scientific Medical Societies (Italy)
  • National CME Commission of the Italian Ministry of Health (Italy)
  • Spanish Accreditation Council for CME (Spain)
  • UEMS-EACCME® (European Union of Medical Specialists)


This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.


This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of HMP Education.


The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a provider-patient relationship. Medical advice of any nature should be sought from an individual’s own provider.

The opinions expressed in this educational activity are those of the faculty and are not attributable to HMP Global or any of its subsidiaries or affiliates. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.


HMP Education is an independent provider of continuing medical education. HMP Education has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

In accordance with our disclosure policies, HMP Education is committed to ensuring balance, independence, objectivity, and scientific rigor for all accredited continuing education. These policies include assigning relevance to, and mitigating, all perceived or real relevant financial relationship (conflicts of interest) between any individual with control over the content and any ineligible company (commercial interest) as defined by the ACCME and CPME.

Any individual with control over accredited content, including planner, faculty, and reviewer, is required to globally disclose:

  1. Individual relationship(s) or lack thereof, and its nature, with any/all ineligible company, and;
  2. Any investigational, off-label, or non-FDA approved content or discussion

HMP Education has reviewed these disclosures, assigned relevance based on the relationship and scope of content, and identified those with the potential to compromise the goals and educational integrity of the education. Relevant relationships, or lack thereof, are shared with the learner.

Education has been independently peer-reviewed to validate content, mitigate identified financial relationships (conflicts of interest), and ensure:

  1. All recommendations involving clinical medicine is based on evidence that is accepted within the medical profession as adequate justification for their indications and contraindications in the care of patients.
  2. All scientific research referred to, reported, or used in accredited continuing education in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection, and analysis.
  3. Content is appropriate, fair and balanced, unbiased, referenced, and non-promotional.

All relevant financial relationships have been mitigated.


The faculty has reported the following:

John Allan, MD: Advisory Board – AbbVie, Acerta/AstraZeneca, ADC Therapeutics, BeiGene, Epizyme, Inc., Genentech Inc, Janssen Biotech, Pharmacyclics, TG Therapeutics; Consultant – AbbVie, Acerta/AstraZeneca, ADC Therapeutics, BeiGene, Janssen Biotech; Grant/Research Support – Celgene (BMS), Genentech Inc, Janssen Biotech, TG Therapeutics; Speakers Bureau – AbbVie, BeiGene, Janssen Biotech, Pharmacyclics

Othman Al-Sawaf, MD: Advisory Board – AbbVie, Roche, Janssen, Ascentage Pharma Group, Gilead; Grant/Research Support – AbbVie, Roche, Janssen, BeiGene; Other Financial or Material Support – AbbVie; Roche, Janssen, Gilead; Speakers Bureau – BeiGene

Jennifer Brown, MD, PhD: Consultant – AbbVie, Acerta/AstraZeneca, BeiGene, Bristol Myers Squibb, Catapult, Eli Lilly & Company, Genentech/Roche, Hutchmed, Janssen, MEI Pharma, Morphosys AG, Novartis, Pfizer, Pharmacyclics, Rigel; Grant/Research Support – BeiGene, Gilead, SecuraBio, Sun Pharmaceuticals, TG Pharmaceuticals

Jan Burger, MD: Grant/Research Support – AstraZeneca, BeiGene, Pharmacyclics; Other Financial or Material Support – Janssen

Asher Chanan-Khan, MD: Advisory Board – Ascentage Pharma Group, Cellectar, Starton Therapeutics; Consultant – BeiGene; Grant/Research Support – Ascentage Pharma Group; Major Stockholder – Alpha2 Pharmaceuticals; Other Financial or Material Support – Ascentage Pharma Group; Royalities – Alpha2 pharmaceuticals

Morton Coleman, MD: Other Financial or Material Support, Principal Investigator – Acerta/AstraZeneca, Adagene, Arcus Biosciences, BeiGene, BMS/Celgene, Boston Biomedical, Inc., Eli Lilly & Company, EMD Serono, Genentech F. Hoffmann-La Roche Ltd., GDK, Hutchinson MedPharma Ltd., Incyte, InnoCare, Ipsen Group, Karyopharm Therapeutics, Klus Pharma Inc., Loxo Oncology, Mei Pharma, Merck Sharp & Dohme Corp, Napo Pharmaceuticals, Novartis, Seattle Genetics

Alexey Danilov, MD, PhD: Consultant – AbbVie, AstraZeneca, BeiGene, BMS, Incyte Corporation, Mei Pharma, MorphoSys AG, Nurix Therapeutics, Inc., Pharmacyclics / Janssen, Roche Genentech, TG Therapeutics; Grant/Research Support – AbbVie, Astra Zeneca, Bayer, BMS, Mei Pharma, Nurix Therapeutics, Inc., TG Therapeutics

Richard Furman, MD: Advisory Board – AbbVie, Acerta/AstraZeneca, BeiGene, Genentech-Roche, Incyte Corporation, Jansen, Loxo Oncology, Mei Pharma, MorphoSys AG, Pharmacyclics, Sanofi/ Genzyme, TG Therapeutics, X4 Pharmaceuticals; Consultant – AbbVie, Acerta/AstraZeneca, BeiGene, Genentech-Roche, Incyte Corporation, Jansen, Pharmacyclics, TG Therapeutics; Grant/ Research Support – Acerta/AstraZeneca, BeiGene, Genentech- Roche, Janssen, TG Therapeutics

Michael Hallek, MD: Advisory Board – AbbVie, AstraZeneca, Bristol Myers Squibb, Gilead, Janssen, Roche; Grant/Research Support – AbbVie, AstraZeneca, Bristol Myers Squibb, Gilead, Janssen, Roche; Speakers Bureau – AbbVie, AstraZeneca, Bristol Myers Squibb, Gilead, Janssen, Roche

Neil Kay, MD: Research Funding- Acerta Pharma BV, Celgene, Genentech, Parmacyclics, Tolero Pharmaceuticals; Data Safety Monitoring Committees- Agios Pharm, AstraZeneca, Celgene, Cytomx Therapeutics, Genentech, Infinity Pharm, Morpho-sys, Pharmacyclics

Anthony Mato, MD: research and/ consulting – AbbVie, Acerta, AstraZeneca, BMS, LOXO, DTRM, Genmab, Nurix, Octopharma, Nurix, TG Therapeutics



Susie Seaman, NP, MSN, CWCN, CWS (nurse planner)
Wound Clinic, Family Health Centers of San Diego
San Diego, California

Ms. Seaman has disclosed no relevant financial relationship with any ineligible company (commercial interest).

HMP Education planners and staff include Kristin Ciszeski; Samantha Conforti; Kelly Jackson, Amrita Kabi, Randy Robbin; and Andrea Zimmerman, EdD.

No HMP Education planner or staff has disclosed a relevant financial relationship with any ineligible company (commercial interest).


HMP Education complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity needs accommodations, please call 609-371-1137.


HMP Education protects the privacy of personal and other information regarding participants, educational partners, and joint providers. HMP Education and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. HMP Education maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2022 by HMP Education. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from HMP Education.


Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by HMP Education may contact Samantha Conforti, Senior Manager, Accreditation and Compliance, by phone at 609-371-1137, by email at or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. Ms. Conforti will review the grievance and respond within 30 days of receiving the complaint.


Supported by independent educational grants from BeiGene USA, Inc, Janssen Biotech Inc and Pharmacyclics, an Abbvie Company.